These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 19665360

  • 1. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C, Jones RJ.
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract] [Full Text] [Related]

  • 2. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec 17; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract] [Full Text] [Related]

  • 3. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M, Douis H, Porfiri E.
    Clin Oncol (R Coll Radiol); 2008 Oct 17; 20(8):657-8. PubMed ID: 18644704
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS.
    Pal SK, Vogelzang NJ.
    Clin Genitourin Cancer; 2011 Sep 17; 9(1):3-5. PubMed ID: 21816688
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H, Bergmann L, Maute L, Eimer C, Otto T.
    Cancer Chemother Pharmacol; 2009 May 17; 63(6):1097-102. PubMed ID: 18818922
    [Abstract] [Full Text] [Related]

  • 11. Temsirolimus for advanced renal-cell carcinoma.
    Fazio N, Dettori M, Lorizzo K.
    N Engl J Med; 2007 Sep 06; 357(10):1050; author reply 1050-1. PubMed ID: 17804854
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma.
    Alemao E, Rajagopalan S, Yang S, Curiel RE, Purvis J, Al MJ.
    J Med Econ; 2011 Sep 06; 14(2):245-52. PubMed ID: 21417551
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Temsirolimus for advanced renal cell carcinoma.
    Figlin RA.
    Clin Adv Hematol Oncol; 2007 Nov 06; 5(11):893. PubMed ID: 18185488
    [No Abstract] [Full Text] [Related]

  • 19. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grünwald V.
    Urology; 2013 Jan 06; 81(1):143-9. PubMed ID: 23273080
    [Abstract] [Full Text] [Related]

  • 20. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
    Lunardi G, Armirotti A, Nicodemo M, Cavallini L, Damonte G, Vannozzi MO, Venturini M.
    Clin Ther; 2009 Aug 06; 31(8):1812-9. PubMed ID: 19808140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.